title: Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient.
authors.forename: V
authors.initials: V
authors.lastname: Panuccio
authors.forename: G
authors.initials: G
authors.lastname: Enia
authors.forename: S
authors.initials: S
authors.lastname: Parlongo
authors.forename: S
authors.initials: S
authors.lastname: Cutrupi
authors.forename: C
authors.initials: C
authors.lastname: Zoccali
mesh_terms: D001629:Bezafibrate / Q000008:administration & dosage / Q000009:adverse effects*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D007690:Polycystic Kidney Diseases / Q000150:complications / Q000628:therapy; D012206:Rhabdomyolysis / Q000139:chemically induced*
chemical_list: D003692:Delayed-Action Preparations; D000960:Hypolipidemic Agents; D001629:Bezafibrate